Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Koppitz

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Combinatorial Chemistry|May 31, 2008
Maximizing efficiency in the production of compound librariesMarcus Koppitz
Drug Discovery Today|May 23, 2006
Automated medicinal chemistryMarcus Koppitz, Knut Eis
Journal of Combinatorial Chemistry|September 13, 2005
Maximizing automation in LC/MS high-throughput analysis and purificationMarcus Koppitz, Andrew Brailsford, Marion Wenz
Bioorganic & Medicinal Chemistry Letters|August 1, 2019
Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitors of microsomal prostaglandin E synthase-1 for the treatment of endometriosisMarcus Koppitz, Nico Bräuer, Antonius Ter Laak, et al.
Journal of Medicinal Chemistry|November 1, 2019
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in VivoLars Wortmann, Bernhard Lindenthal, Peter Muhn, et al.
Molecular Cancer Therapeutics|February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor ActivityAntje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Journal of Medicinal Chemistry|June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor ModelsUlrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Journal of Medicinal Chemistry|April 28, 2020
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 KinaseVolker K Schulze, Ulrich Klar, Dirk Kosemund, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Combinatorial Chemistry|May 31, 2008
Maximizing efficiency in the production of compound librariesMarcus Koppitz
Drug Discovery Today|May 23, 2006
Automated medicinal chemistryMarcus Koppitz, Knut Eis
Journal of Combinatorial Chemistry|September 13, 2005
Maximizing automation in LC/MS high-throughput analysis and purificationMarcus Koppitz, Andrew Brailsford, Marion Wenz
Bioorganic & Medicinal Chemistry Letters|August 1, 2019
Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitors of microsomal prostaglandin E synthase-1 for the treatment of endometriosisMarcus Koppitz, Nico Bräuer, Antonius Ter Laak, et al.
Journal of Medicinal Chemistry|November 1, 2019
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in VivoLars Wortmann, Bernhard Lindenthal, Peter Muhn, et al.
Molecular Cancer Therapeutics|February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor ActivityAntje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Journal of Medicinal Chemistry|June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor ModelsUlrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Journal of Medicinal Chemistry|April 28, 2020
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 KinaseVolker K Schulze, Ulrich Klar, Dirk Kosemund, et al.
Pageof 1